ArticleFrontiers in plant science2023
Hydroxyanthracene derivates citotoxicity: A differential evaluation between single molecule and whole plant extract.
Article in Frontiers in plant science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Untargeted Metabolomics for Profiling of Cascara, Senna, Rhubarb, and Frangula Metabolites.Metabolites · 2025Article
- Deciphering the Mechanisms Underlying the Antitumor Effects of Eucalyptus Essential Oil and Its Component 3-Cyclohexene-1-Methanol Against Human Colon Cancer Cells.International journal of molecular sciences · 2025Article
- UPLC-MS/MS Analysis of Hydroxyanthracene Derivatives in Botanical Food Products and Supplements: Surveillance of the Italian Market.Foods (Basel, Switzerland) · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxyanthracene derivates (HADs) are a group of natural or synthetic compounds with a wide range of biological activities (for instance, anti-inflammatory, antibacterial, and antiarthritic). In addition, because of their properties for helping the normal bowel function, HADs are widely used in constipation as pharmacological drugs and nutritional supplements. Nevertheless, during the past years, a safety usage of HAD products has been under consideration because some studies reported that HADs are not lacking toxicity (i.e., genotoxic and carcinogenic activity). Thus, the first objective of this study is to shed light on the large variability in composition of botanical food supplements containing HAD by a systematic analysis of the qualitative and quantitative composition of a cohort of extracts and raw materials of plants with high levels of anthraquinones commercially available (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.